[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AponiaAnalytics Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1816152863069925376.png) aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 5005 followers
Created: 2025-07-08 13:41:18 UTC

$NKTR $CRVS 
Conjunctivitis has emerged as a persistent adverse effect tied specifically to IL-4/IL-13 pathway inhibition in atopic dermatitis (AtD) biologics like Dupixent and Ebglyss. New evidence links this to IL-4RA expression on conjunctival goblet cells—creating an inherent ocular vulnerability in this mechanism.

This opens a differentiated safety window—and possibly a major market advantage—for $NKTR (Rezpeg) and $CRVS (Soquelitinib). Both use novel mechanisms (Treg proliferation and ITK inhibition, respectively) and have shown zero conjunctivitis events across >400 patients combined. If replicated in Phase 3, this profile could drive payer and prescriber preference, especially in mild-to-moderate AtD segments or ocular-sensitive populations.

Start building long positions in $NKTR and $CRVS while they trade below institutional radar. The safety delta vs. IL-4/13 inhibitors could become a defining differentiator by 2026.


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942579751937294778/c:line.svg)

**Related Topics**
[atd](/topic/atd)
[$crvs](/topic/$crvs)
[$nktr](/topic/$nktr)

[Post Link](https://x.com/AponiaAnalytics/status/1942579751937294778)